Metal-based anticancer compounds: Design, synthesis and biological results

4^th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Frankline K Keter

Accepted Abstracts: J Cancer Sci Ther

Abstract :

Metal compounds, as potential drugs, continue to receive great attentionsince the discovery of cisplatin. Cisplatin is used in the treatment of several types of cancers and is found in 50%-70% of all chemotherapy schemes administered to cancer patients. It acts by binding the DNA molecule. Unfortunately metal-based drugs are either inactive or have sideeffects when administered to the patients. Several attempts have been made to prepare new metal compoundsthat would show improved efficacies and less toxicity. This has led to a surge of new potential anticancer metallo-drugs, including ruthenium, palladium and gold compounds. In this study several palladium(II) and platinum (II) compounds, employing pyrazoles as ligands, have been prepared as anticancer agents. The results have shown that the platinum(II) compounds induce DNA strand breaks and activates caspase-3 in CaSki, HeLa, and p53 mutant Jurkatcells that leads to apoptosis. Furthermore, a series of phosphinogold(I) dithiocarbamate complexes that show good anticancer activity against human cervical epithelioidcarcinoma (HeLa) cells and better selectivity than cisplatin have also been prepared. The lecturewill highlight the synthetic journey of these compounds, structure elucidation, and some exciting anticancer results.A brief summary of how nanotechnology will be employed to further improve on the efficacy of the compounds, and possibly reduce any side effects, will also be mentioned.

Biography :

Frankline K Keter completed his PhD in inorganic chemistry from the University of Johannesburg (2008) and is experienced in synthesis and nanotechnology worklinked to drug discovery and development. He worked as a postdoctoral research fellow at the University of Pretoria, before joiningMintek as a full-time research scientist in the DST/Mintek Nanotechnology Innovation Centre (NIC), Biolabels unit. His work is well captured in a provisional patent and publications in international peer reviewed journals.